Lakewood-Amedex Biotherapeutics, Inc.
LABT
$2.30
-$0.02-0.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 571.47% | 89.24% | 22.60% | 203.89% | -12.66% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | -14.29% | -29.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 494.56% | 63.44% | -17.41% | 105.97% | -42.60% |
| Operating Income | -494.56% | -63.44% | 17.41% | -105.97% | 42.60% |
| Income Before Tax | -475.09% | -71.11% | 12.83% | 1.49% | 38.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -475.09% | -71.11% | 12.83% | 1.49% | 38.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -475.09% | -71.11% | 12.83% | 1.49% | 38.16% |
| EBIT | -494.56% | -63.44% | 17.41% | -105.97% | 42.60% |
| EBITDA | -495.49% | -63.55% | 17.43% | -106.17% | 42.62% |
| EPS Basic | -65.14% | -36.14% | 4.17% | 1.84% | -8.72% |
| Normalized Basic EPS | -181.30% | -69.84% | 13.13% | -112.83% | 38.23% |
| EPS Diluted | -65.14% | -36.14% | 4.17% | 1.84% | -8.72% |
| Normalized Diluted EPS | -181.30% | -69.84% | 13.13% | -112.83% | 38.23% |
| Average Basic Shares Outstanding | 104.43% | 0.75% | 0.36% | 0.36% | 0.13% |
| Average Diluted Shares Outstanding | 104.43% | 0.75% | 0.36% | 0.36% | 0.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |